SFDA Drug Registration: A Complete 2026 Guide for UK Pharmaceutical Exporters

Saudi Arabia is the largest pharmaceutical market in the Gulf and one of the most strategically important destinations for UK pharmaceutical exporters. The Kingdom is undertaking a programme of healthcare modernisation and self sufficiency under Vision 2030, NUPCO has consolidated public sector procurement, and tertiary hospitals such as King Faisal Specialist Hospital, King Fahad Medical City and the National Guard system continue to demand specialty, oncology, and rare disease medicines that are not yet manufactured locally.

For UK manufacturers and licensed wholesale exporters, all of this is mediated through one body: the Saudi Food and Drug Authority. Without an understanding of how the SFDA works, what it requires, and where the practical pathways are, it is very easy to spend twelve months and significant capital before discovering that a registration is incomplete, a CPP is the wrong format, or a tender bid is non compliant on a clause that nobody flagged at the start.

This guide is written for UK pharmaceutical exporters, MHRA-licensed wholesalers, and Saudi importers who need a practical, end to end view of the 2026 SFDA drug registration process. It covers the regulator itself, the four routes into the Saudi market, the documentation package, registration timelines, the 2026 NUPCO localisation framework, Hajj seasonal supply, cold chain expectations, common pitfalls, and how Euro Biom supports the journey from MHRA paperwork to Saudi hospital delivery.

Why SFDA Matters: The Saudi Market in 2026

Saudi Arabia accounts for roughly 60 percent of total pharmaceutical spending across the GCC and is forecast to remain the largest market in the region throughout the decade. The combination of a young population, expanding insurance coverage, the rapid build out of tertiary care under the Health Sector Transformation Programme, and the centralisation of public procurement through NUPCO has produced a market that is large, organised, and increasingly demanding of regulatory rigour.

Three structural realities shape what UK exporters encounter:

• Public hospitals dominate volume. Saudi public sector facilities, including Ministry of Health hospitals, the National Guard Health Affairs system, KFSH, KFMC, KAMC, and the Ministry of Defence hospitals, account for the bulk of pharmaceutical consumption. Most of this volume now flows through NUPCO contracts rather than facility level tenders.
• Specialty and complex therapies are the gap. Generics and routine hospital products are increasingly localised to Saudi manufacturing under Vision 2030. Specialty oncology, rare disease, biologics, and named patient supply remain heavily reliant on imports, particularly from the UK and EU under MHRA and EMA quality frameworks.
• The SFDA is the gatekeeper. Whether the route is full registration, NUPCO tender, named patient supply, or shortage exemption, every imported medicine eventually passes under SFDA scrutiny. Building a compliant registration and documentation pathway is therefore the prerequisite to any Saudi market activity.

For more on the broader Saudi opportunity, see our UK pharmaceutical exporter to Saudi Arabia landing page, and the wider GCC pharmaceutical exporter overview for context on how Saudi sits within the regional regulatory map.

SFDA Structure: How the Regulator Is Organised

The Saudi Food and Drug Authority is an independent government body reporting directly to the Council of Ministers. It was established in 2003 and has since expanded its scope to cover human medicines, veterinary products, medical devices, food, cosmetics, and pesticides. The structure most relevant to UK pharmaceutical exporters is the SFDA Drug Sector.

Within the Drug Sector, several departments matter for any registration project:

• Department of Drug Registration. Manages the full marketing authorisation application process, dossier review, and SDR (Saudi Drug Registration) electronic system through which all submissions flow.
• Department of Drug Safety and Pharmacovigilance. Oversees post marketing surveillance, adverse event reporting, and any safety variation submissions.
• Department of Inspection and Licensing. Audits Saudi local agents, inspects manufacturing sites where applicable, and licences pharmaceutical companies operating in the Kingdom.
• Department of Importing and Exporting. Issues shipment level import permits, manages the Special Access Program, and handles emergency or shortage exemption requests.
• SFDA Quality Control Laboratories. Located in Riyadh and Dammam, these laboratories perform batch testing, sample analysis, and product release for selected categories of imported medicines.

The SFDA also coordinates with the Gulf Health Council to administer the GCC Centralised Registration procedure, which permits a single dossier to be reviewed for marketing authorisation in multiple Gulf states simultaneously. For UK exporters with regional ambition, registering through GCC Centralised Registration can shorten the cumulative timeline across Saudi Arabia, the UAE, Qatar, Kuwait, Bahrain, and Oman, although in practice individual member state confirmations still apply.

Four Routes into the Saudi Market

UK exporters typically encounter one of four pathways to supplying medicines into Saudi Arabia. Choosing the right pathway depends on the product category, urgency, volume, and whether the medicine has, or could realistically obtain, a Saudi marketing authorisation.

1. Full SFDA Marketing Authorisation

Required for any product that will be supplied at scale into the Saudi market on a routine basis. The marketing authorisation holder is the foreign manufacturer (in our case typically a UK based pharmaceutical company), represented in the Kingdom by an authorised local agent. A full eCTD dossier is submitted via the SFDA SDR portal, reviewed by the Department of Drug Registration, and ultimately granted as a renewable authorisation (typically valid for five years, subject to variation submissions).

Full registration is the prerequisite for inclusion in NUPCO routine pharmaceutical tenders. It also supports private sector hospital and pharmacy distribution.

2. Named Patient and Special Access Program

The SFDA Special Access Program (SAP) permits the import of unregistered medicines for individual patients or small cohorts where no registered alternative exists locally. Applications are made by the prescribing institution (often a tertiary hospital such as KFSH or KFMC) through their pharmacy department, with SFDA Department of Importing and Exporting issuing a shipment specific authorisation.

SAP is the standard route for rare disease medicines, specialty oncology agents not yet registered in Saudi Arabia, gene therapies, paediatric formulations, and named patient compassionate use cases. UK exporters with MHRA Wholesale Dealer Authorisation are well placed to support SAP requests because the UK regulatory framework, MHRA Special Import Licence and Regulation 167 supply, maps cleanly onto the SFDA expectations. See our named patient supply service for the UK side process.

3. NUPCO Tender Supply

The National Unified Procurement Company is the consolidated procurement arm for Saudi public hospitals. NUPCO publishes structured tenders covering generics, branded products, hospital pharmaceuticals, vaccines, oncology, and specialty therapy areas. Eligibility to bid requires SFDA marketing authorisation in place, and increasingly, evidence of either local manufacturing or a localisation plan under the Vision 2030 framework.

UK exporters can support NUPCO supply in two ways: as the marketing authorisation holder bidding directly through their authorised local agent, or as a sub supplier providing the finished dossier and product to a Saudi distributor that holds the NUPCO contract. Our tender and government supply service covers the documentation pack and bid coordination side.

4. Shortage and Emergency Exemption

When the SFDA identifies a critical shortage of an essential medicine, or where a Saudi public hospital faces an immediate supply failure, the Department of Importing and Exporting can issue an emergency import authorisation outside the normal registration framework. UK suppliers with verified MHRA WDA status, GDP cold chain capability, and rapid Heathrow despatch are particularly well positioned for these requests because turnaround is measured in days rather than months.

Shortage exemptions are also a common pathway during Hajj and Umrah seasons (covered in detail later in this guide) and during outbreak responses such as the recurring meningitis vaccination campaigns required for incoming pilgrims.

SFDA Documentation Requirements

The SFDA registration dossier is structured around the ICH Common Technical Document (CTD) format, with regional supplements that reflect Saudi specific requirements. For a UK manufactured product going through full marketing authorisation, the core documentation package contains the following elements.

The CPP is the single document that most UK exporters underestimate. The SFDA requires a current CPP issued by the MHRA, in WHO format, no more than 24 months old at submission, naming the specific manufacturing site and the approved indications. UK manufacturers obtain the CPP via the MHRA Export Certificate service, with current turnaround running between four and eight weeks. Building the CPP request into the project plan early is essential, especially when an SFDA submission deadline is fixed.

Batch release certification is the second area where UK exporters often need to coordinate carefully. Each batch shipped to Saudi Arabia must be accompanied by a Qualified Person batch release certificate, issued either by the manufacturer or by a UK-licensed contract release site. Where the UK exporter is not the manufacturer, the wholesale exporter coordinates with the manufacturer's QP to obtain the release documentation in advance of despatch.

For products supplied under named patient or SAP routes, the documentation requirement is reduced: the SFDA expects an MHRA CPP or equivalent country of origin certificate, a CoA, and batch documentation, alongside a clinical justification and local agent SAP application. Full eCTD dossier submission is not required for individual SAP shipments.

SFDA Registration Timeline

Timelines for SFDA registration vary by product category, dossier completeness, and the specific pathway chosen. The following ranges reflect 2025 and early 2026 outcomes for UK manufactured products with complete dossiers:

• New chemical entity, full registration: 18 to 24 months from dossier submission to marketing authorisation, including SFDA scientific review, deficiency response cycles, and final approval.
• Generic, full registration: 9 to 14 months, faster where the reference product is already SFDA registered and the bioequivalence study uses an SFDA accepted comparator.
• Biosimilar, full registration: 14 to 20 months, with the longer end reflecting comparative analytical characterisation and clinical similarity review.
• Orphan and rare disease, expedited review: 9 to 12 months, where the SFDA Fast Track designation applies. Pre approval by the MHRA, EMA, FDA, or PMDA significantly increases the likelihood of Fast Track designation.
• Variation (new strength, new manufacturing site): 3 to 9 months depending on classification (Type IA, Type IB, or Type II under SFDA variation guideline).
• Named patient and SAP application: 3 to 14 days from local agent submission to import authorisation, with most cases issued within 5 working days when documentation is complete.
• Shortage and emergency exemption: 24 to 96 hours when SFDA confirms the shortage status and the UK supplier delivers the documentation pack within the same window.

The single biggest cause of timeline overrun in our experience is incomplete documentation at first submission. SFDA reviewers issue formal deficiency letters that must be answered within defined response windows, and each deficiency cycle adds 60 to 120 days to the overall timeline. UK exporters that invest in dossier readiness review before submission, with their local agent and where possible an external SFDA regulatory consultant, typically halve the deficiency cycle count compared to those that submit on the assumption that reviewers will request clarification.

NUPCO 2026 Localisation Rules

The single most discussed regulatory development of the past 18 months in the Saudi pharmaceutical market is the NUPCO localisation framework. Aligned with the broader Saudi Vision 2030 industrial localisation programme, the framework is designed to grow domestic pharmaceutical manufacturing as a share of total public hospital procurement. For UK exporters, understanding what is in scope and what is out of scope is critical to commercial planning.

What the framework requires

For routine pharmaceutical tenders covering high volume hospital products, primary care medicines, and generics, NUPCO 2026 evaluation criteria favour suppliers that meet at least one of the following:

• The product is manufactured in Saudi Arabia at an SFDA-licensed manufacturing site
• The marketing authorisation holder has a binding technology transfer agreement with a Saudi manufacturer with a defined transfer timeline
• The product holds Saudi National Industrial Strategy classification under one of the priority categories

Bidders that cannot meet any of these criteria face price, evaluation, and award disadvantages on routine NUPCO tender lots. In practical terms, foreign manufactured generics that compete head to head with locally produced alternatives are increasingly unlikely to secure NUPCO awards.

What is exempt from the framework

The localisation rules explicitly carve out segments where Saudi domestic manufacturing capacity is either non existent or insufficient. The exempt categories are precisely the segments where UK exporters with MHRA quality credentials are most relevant:

• Named patient and Special Access Program supplies
• Products on the SFDA shortage list (which is updated regularly and includes a substantial number of specialty medicines)
• Orphan drugs and ultra rare disease therapies
• Specialty oncology, particularly antibody therapies, cell therapies, and recently approved targeted agents
• Biologics where no Saudi manufacturing exists
• Clinical trial supplies under approved Saudi clinical trials
• Vaccines for emergency, outbreak, or Hajj seasonal response where local capacity cannot meet demand
• Reference product supply for Saudi based bioequivalence and biosimilarity studies (see our reference listed drug supply service)

Implications for UK exporters

The right strategic positioning for UK exporters is to recognise that the localisation framework actively reinforces the value of MHRA-licensed UK supply in the segments where the framework cannot reach. Specialty, named patient, shortage, orphan, oncology and rare disease are growing not shrinking. UK exporters that align their Saudi entry strategy around these exempt segments, rather than competing for routine generic tenders, are positioned in alignment with both the regulatory trajectory and the clinical reality of Saudi tertiary care.

Hajj and Umrah Seasonal Supply

Hajj and Umrah generate a uniquely large and time concentrated pharmaceutical demand profile that does not exist in any other market. Each year, approximately 2 million pilgrims attend Hajj and a further 13 to 20 million complete Umrah, with the bulk of pilgrim flows arriving in Mecca and Medina via Jeddah and Madinah airports. The Saudi Ministry of Health prepares months in advance to provision medical supplies, and the SFDA coordinates expedited import authorisations to support the seasonal stock build.

For UK exporters with cold chain capability, Heathrow proximity, and existing SFDA registered local agents, several supply categories present recurring opportunities:

• ACWY meningococcal vaccine. Saudi regulations require all incoming pilgrims to hold a valid ACWY vaccination certificate. The Ministry of Health and SFDA procure substantial volumes of ACWY vaccine each year through NUPCO and dedicated Hajj health supply contracts. UK and EU manufacturers regularly contribute to this volume through MHRA-licensed UK exporters.
• Antibiotic and antiviral stock. Heat exhaustion, respiratory infection, and gastrointestinal complaints rise sharply during Hajj. The Ministry of Health expands antibiotic and antiviral stock at Mecca, Mina, and Madinah hospitals during the season. Shortage exemptions are commonly issued where established Saudi supply does not meet the forecast peak.
• Oral rehydration salts and IV fluids. The combination of midsummer Hajj timing and the physical demand of the rituals produces high demand for rehydration therapy.
• Cardiology and chronic disease maintenance. A high proportion of Hajj pilgrims are elderly with multiple chronic conditions. Hospitals in Mecca and Madinah expand maintenance medication stocks for cardiology, diabetes, COPD, and renal management during the season.

Critical operational point: order lead times tighten significantly in the 60 days leading up to Hajj. Most contract awards finalise four to six months in advance of the season. UK exporters that intend to participate in any Hajj supply category should be in dialogue with their Saudi local agent, and ideally with NUPCO or the Ministry of Health buyer concerned, no later than the end of Q4 of the prior calendar year.

Cold Chain Requirements: Heathrow to Riyadh and Jeddah

A substantial proportion of UK pharmaceutical exports to Saudi Arabia involve cold chain product, including biologics, insulin, vaccines, monoclonal antibodies, oncology infusions, and named patient specialty therapies. The SFDA cold chain requirements are well defined, and they are enforced rigorously at port of entry inspection.

The core requirements that UK exporters must meet are:

• Validated temperature-controlled storage. The UK wholesale exporter must hold the product in MHRA-validated temperature-controlled facilities at the specified storage temperature (typically 2 to 8 degrees Celsius for cold chain products, or the manufacturer specified deep frozen range for biologics requiring it).
• Qualified shipping containers. Validated active or passive temperature-controlled shipping containers, with documented qualification at the operating ambient profile expected for the Heathrow to Saudi Arabia route, including the elevated ground temperatures encountered in Riyadh and Jeddah during summer.
• Continuous temperature monitoring. A calibrated temperature data logger must accompany the consignment from origin packing through to destination acceptance. The logger record is one of the documents inspected by SFDA at port of entry, and any temperature excursion outside the approved range must be reviewed and either accepted or rejected by the consignee under defined deviation procedures.
• Stability data covering the transit profile. The manufacturer stability dossier must support the actual conditions experienced during transit. For most CHMP and MHRA approved cold chain products, the existing stability data is sufficient, but for novel modalities, additional bridging stability studies are sometimes required.
• GDP-compliant transport network. The full chain from UK warehouse, to airline ramp, through Heathrow cargo handling, into the destination airport (typically King Khalid International Airport Riyadh, King Abdulaziz International Airport Jeddah, or Prince Mohammad Bin Abdulaziz Airport Madinah), and onward to the SFDA registered local agent or hospital, must be GDP compliant.

Heathrow to Riyadh direct flights run multiple times daily with a flight time of approximately six and a half hours. Heathrow to Jeddah is similar at approximately six hours. Same day despatch from a Heathrow proximate UK warehouse is achievable for urgent or emergency consignments, with delivery to the destination hospital typically within 48 to 72 hours including SFDA port of entry inspection.

For more on the practical mechanics of cold chain logistics, see our UK cold chain pharmaceutical supply page and the detailed pharma cold chain logistics guide.

Common Pitfalls (and How to Avoid Them)

Across SFDA registration projects, the same eight pitfalls account for the majority of timeline overruns and tender failures. Each is straightforward to avoid with the right preparation.

1. Out of date or wrong format CPP

The MHRA issues CPPs in WHO format, but UK manufacturers occasionally rely on internal export certificates that are not in WHO format and that the SFDA will not accept. The CPP must also be no more than 24 months old at the time of dossier submission. Build the CPP request into the project plan four to six months before the intended SFDA filing window.

2. Incomplete batch release certification

Each batch shipped requires a QP batch release certificate. UK exporters that are not the manufacturer must confirm with the MA holder how the certificate will be issued, who the named QP is, and what the lead time is for each release. Building this into the export pack template avoids last minute despatch delays.

3. Arabic labelling errors

The SFDA labelling rule set is detailed: outer carton, primary container label, and patient information leaflet must each meet specific Arabic translation, layout, and content rules. The rules are updated periodically. Engaging a Saudi regulatory consultant to review the labelling pack before submission, and again before each batch despatch, materially reduces rejection rates.

4. Local agent selection

The local agent is not just an administrative formality. The agent's commercial network, hospital relationships, NUPCO standing, and operational systems all materially affect the speed and success of the UK exporter's market entry. Selecting an agent on the basis of a low retainer alone is one of the most common strategic errors.

5. Misreading the localisation framework

UK exporters sometimes assume that the NUPCO localisation rules apply to all categories. They do not. Specialty, named patient, shortage, orphan, oncology, and rare disease are exempt. Misreading the framework can lead to the wrong commercial strategy and, in some cases, the abandonment of viable Saudi market entry plans.

6. Cold chain temperature excursion handling

Even with validated shipping, occasional excursions occur. Where the consignment lacks a documented deviation review procedure agreed with the consignee in advance, an excursion can result in a quarantined consignment for weeks while the parties negotiate handling. A documented deviation procedure embedded in the supply agreement avoids this.

7. Tender bid documentation gaps

NUPCO tender packs are detailed and require a specific document set that includes SFDA marketing authorisation evidence, GMP certification, batch release procedures, pricing, lead times, and at times, technology transfer letters of intent. Submitting an incomplete pack is the single most common cause of tender disqualification.

8. Treating named patient as an afterthought

UK exporters with a strong UK based named patient practice sometimes underestimate how different the SAP application looks in Saudi Arabia. The application is made by the prescribing institution, not by the UK supplier, and the documentation requirements include a clinical justification, an SFDA SAP form, the country of origin certificate, and a CoA. Aligning the UK supplier documentation pack to the SFDA SAP requirements upfront accelerates each subsequent named patient request from weeks to days.

How Euro Biom Supports UK Exporters and Saudi Importers

Euro Biom is a UK MHRA-licensed pharmaceutical wholesale exporter, holding Wholesale Dealer Authorisation WDA(H) 59239. We do not manufacture medicines, and we are not a regulatory consultancy. What we do is operate the UK supply leg of an SFDA compliant pharmaceutical export, working closely with manufacturers, marketing authorisation holders, Saudi importers, and SFDA registered local agents.

Across the SFDA pathway, our role typically covers:

• UK side documentation. Coordinating MHRA Certificate of Pharmaceutical Product procurement with the manufacturer or MA holder, GMP certificate retrieval, and the GDP-compliant export pack including CoA, batch release, packing list, and chamber-attested commercial invoice.
• Cold chain logistics from Heathrow. GDP-validated temperature-controlled storage, qualified shipping containers, calibrated data loggers, and Heathrow despatch with direct routing to King Khalid International Airport Riyadh, King Abdulaziz International Airport Jeddah, or other Saudi ports of entry.
• Named patient and SAP supply. Working with Saudi tertiary hospital pharmacies (KFSH, KFMC, KAMC, NGHA) and their local agents to deliver SAP authorised consignments within the SFDA timelines, often inside 5 working days from confirmed enquiry.
• NUPCO tender support. Documentation packs for Saudi importers and local agents bidding into NUPCO tenders, including supply chain assurance evidence, GDP certification, lead time commitments, and pricing letters.
• Shortage exemption supply. Rapid response on SFDA shortage list items where Heathrow proximity, MHRA-licensed inventory, and same day despatch capability are decisive.
• Hajj and Umrah seasonal supply. Coordination with Saudi importers for ACWY vaccine, antibiotic, antiviral, IV fluid, and chronic disease maintenance medicine in the build up to the Hajj season.
• Reference listed drug supply. MHRA-sourced reference product for Saudi based bioequivalence and biosimilarity studies, supporting Saudi manufacturing localisation efforts.

For more on the specific commercial entry points to the Saudi market, see our pharmaceutical exporter to Saudi Arabia page. For the wider regional context, see the UK pharmaceutical exporter to GCC overview. For the UK side regulatory framework that underpins SFDA acceptance of MHRA documentation, see our WDA licensing guide and the broader Saudi Arabia and UAE import guide. Detail on Euro Biom's MHRA standards is on the compliance page, and our overall service description is on the services page.